Foscarnet prophylaxis of cytomegalovirus infections in patients undergoing allogeneic bone marrow transplantation (BMT): A dose-finding study

S. Bregante, S. Bertilson, E. Tedone, M. T. Van Lint, G. Trespi, N. Mordini, G. Berisso, F. Gualandi, T. Lamparelli, O. Figari, F. Benvenuto, A. M. Raiola, A. Bacigalupo

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

This is a dose-finding study using foscarnet for CMV prophylaxis after allogeneic bone marrow transplantation (BMT) in 20 high risk patients (unrelated donors, or T cell depleted, and/or advanced disease). Foscarnet was started on day +1 after BMT and continued until day +100. We explored four different dose levels, patients being entered at the lowest dose level until one patient experiences CMV-reactivation, identified as two consecutive positive CMV antigenemias (CMVAg-emia). The four dose levels expressed as mg/kg/day between days 1 and 30 (induction) and between days 31 and 100 (maintenance) were respectively: dose level I = 60/30 (n = 5); dose level II = 120/60 (n = 4); dose level III = 120/90 (n = 5) and dose level IV = 120/120 (n = 6). All patients showed engraftment: PMN ≥ 0.5 x 109/l at a median interval of 16, 21, 17, 15 days after BMT, and Plt ≥ 30 x 109/l on days 19, 16, 17, 17 respectively. CMVAg-emia was seen in 10 patients at a median interval of 53 days post-BMT (range 33-89) with a median of 10 CMV antigen+ cells (range 1-16). There was a dose effect of foscarnet on CMVAg-emia: respectively 4/5 patients (80%), 2/4 (50%), 3/5 (60%) and 1/6 (18%) at dose levels I, II, III, IV (P = 0.1). CMV disease was seen in 3/9 (33%) at dose levels I, II and 0/11 at dose levels III, IV (P = 0.07). The median number of CMV antigen-positive cells at diagnosis of CMV infection was different: 13 in dose levels I-II and two in dose levels III-IV (P = 0.01). Increased creatininine was seen in 15 patients with a mean of 1.8 mg% (range 1.5-5.7) and was the cause of discontinuation in nine patients (45%). Renal toxicity was reversible in all nine patients. Overall actuarial TRM at 2 years was 31%: 47% for patients at dose levels I-II and 19% for patients at dose levels III-IV. In conclusion, foscarnet exhibits a dose-dependent prophylactic effect on CMVAg-emia, CMV disease and transplant-related mortality with acceptable and reversible renal toxicity.

Original languageEnglish
Pages (from-to)23-29
Number of pages7
JournalBone Marrow Transplantation
Volume26
Issue number1
Publication statusPublished - 2000

Fingerprint

Foscarnet
Homologous Transplantation
Cytomegalovirus Infections
Bone Marrow Transplantation
Kidney
Antigens
Unrelated Donors

Keywords

  • Bone marrow transplantation
  • Cytomegalovirus
  • Foscarnet

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Foscarnet prophylaxis of cytomegalovirus infections in patients undergoing allogeneic bone marrow transplantation (BMT) : A dose-finding study. / Bregante, S.; Bertilson, S.; Tedone, E.; Van Lint, M. T.; Trespi, G.; Mordini, N.; Berisso, G.; Gualandi, F.; Lamparelli, T.; Figari, O.; Benvenuto, F.; Raiola, A. M.; Bacigalupo, A.

In: Bone Marrow Transplantation, Vol. 26, No. 1, 2000, p. 23-29.

Research output: Contribution to journalArticle

@article{b88cc834bbab4f468dfaa1f1a0fa2d69,
title = "Foscarnet prophylaxis of cytomegalovirus infections in patients undergoing allogeneic bone marrow transplantation (BMT): A dose-finding study",
abstract = "This is a dose-finding study using foscarnet for CMV prophylaxis after allogeneic bone marrow transplantation (BMT) in 20 high risk patients (unrelated donors, or T cell depleted, and/or advanced disease). Foscarnet was started on day +1 after BMT and continued until day +100. We explored four different dose levels, patients being entered at the lowest dose level until one patient experiences CMV-reactivation, identified as two consecutive positive CMV antigenemias (CMVAg-emia). The four dose levels expressed as mg/kg/day between days 1 and 30 (induction) and between days 31 and 100 (maintenance) were respectively: dose level I = 60/30 (n = 5); dose level II = 120/60 (n = 4); dose level III = 120/90 (n = 5) and dose level IV = 120/120 (n = 6). All patients showed engraftment: PMN ≥ 0.5 x 109/l at a median interval of 16, 21, 17, 15 days after BMT, and Plt ≥ 30 x 109/l on days 19, 16, 17, 17 respectively. CMVAg-emia was seen in 10 patients at a median interval of 53 days post-BMT (range 33-89) with a median of 10 CMV antigen+ cells (range 1-16). There was a dose effect of foscarnet on CMVAg-emia: respectively 4/5 patients (80{\%}), 2/4 (50{\%}), 3/5 (60{\%}) and 1/6 (18{\%}) at dose levels I, II, III, IV (P = 0.1). CMV disease was seen in 3/9 (33{\%}) at dose levels I, II and 0/11 at dose levels III, IV (P = 0.07). The median number of CMV antigen-positive cells at diagnosis of CMV infection was different: 13 in dose levels I-II and two in dose levels III-IV (P = 0.01). Increased creatininine was seen in 15 patients with a mean of 1.8 mg{\%} (range 1.5-5.7) and was the cause of discontinuation in nine patients (45{\%}). Renal toxicity was reversible in all nine patients. Overall actuarial TRM at 2 years was 31{\%}: 47{\%} for patients at dose levels I-II and 19{\%} for patients at dose levels III-IV. In conclusion, foscarnet exhibits a dose-dependent prophylactic effect on CMVAg-emia, CMV disease and transplant-related mortality with acceptable and reversible renal toxicity.",
keywords = "Bone marrow transplantation, Cytomegalovirus, Foscarnet",
author = "S. Bregante and S. Bertilson and E. Tedone and {Van Lint}, {M. T.} and G. Trespi and N. Mordini and G. Berisso and F. Gualandi and T. Lamparelli and O. Figari and F. Benvenuto and Raiola, {A. M.} and A. Bacigalupo",
year = "2000",
language = "English",
volume = "26",
pages = "23--29",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Foscarnet prophylaxis of cytomegalovirus infections in patients undergoing allogeneic bone marrow transplantation (BMT)

T2 - A dose-finding study

AU - Bregante, S.

AU - Bertilson, S.

AU - Tedone, E.

AU - Van Lint, M. T.

AU - Trespi, G.

AU - Mordini, N.

AU - Berisso, G.

AU - Gualandi, F.

AU - Lamparelli, T.

AU - Figari, O.

AU - Benvenuto, F.

AU - Raiola, A. M.

AU - Bacigalupo, A.

PY - 2000

Y1 - 2000

N2 - This is a dose-finding study using foscarnet for CMV prophylaxis after allogeneic bone marrow transplantation (BMT) in 20 high risk patients (unrelated donors, or T cell depleted, and/or advanced disease). Foscarnet was started on day +1 after BMT and continued until day +100. We explored four different dose levels, patients being entered at the lowest dose level until one patient experiences CMV-reactivation, identified as two consecutive positive CMV antigenemias (CMVAg-emia). The four dose levels expressed as mg/kg/day between days 1 and 30 (induction) and between days 31 and 100 (maintenance) were respectively: dose level I = 60/30 (n = 5); dose level II = 120/60 (n = 4); dose level III = 120/90 (n = 5) and dose level IV = 120/120 (n = 6). All patients showed engraftment: PMN ≥ 0.5 x 109/l at a median interval of 16, 21, 17, 15 days after BMT, and Plt ≥ 30 x 109/l on days 19, 16, 17, 17 respectively. CMVAg-emia was seen in 10 patients at a median interval of 53 days post-BMT (range 33-89) with a median of 10 CMV antigen+ cells (range 1-16). There was a dose effect of foscarnet on CMVAg-emia: respectively 4/5 patients (80%), 2/4 (50%), 3/5 (60%) and 1/6 (18%) at dose levels I, II, III, IV (P = 0.1). CMV disease was seen in 3/9 (33%) at dose levels I, II and 0/11 at dose levels III, IV (P = 0.07). The median number of CMV antigen-positive cells at diagnosis of CMV infection was different: 13 in dose levels I-II and two in dose levels III-IV (P = 0.01). Increased creatininine was seen in 15 patients with a mean of 1.8 mg% (range 1.5-5.7) and was the cause of discontinuation in nine patients (45%). Renal toxicity was reversible in all nine patients. Overall actuarial TRM at 2 years was 31%: 47% for patients at dose levels I-II and 19% for patients at dose levels III-IV. In conclusion, foscarnet exhibits a dose-dependent prophylactic effect on CMVAg-emia, CMV disease and transplant-related mortality with acceptable and reversible renal toxicity.

AB - This is a dose-finding study using foscarnet for CMV prophylaxis after allogeneic bone marrow transplantation (BMT) in 20 high risk patients (unrelated donors, or T cell depleted, and/or advanced disease). Foscarnet was started on day +1 after BMT and continued until day +100. We explored four different dose levels, patients being entered at the lowest dose level until one patient experiences CMV-reactivation, identified as two consecutive positive CMV antigenemias (CMVAg-emia). The four dose levels expressed as mg/kg/day between days 1 and 30 (induction) and between days 31 and 100 (maintenance) were respectively: dose level I = 60/30 (n = 5); dose level II = 120/60 (n = 4); dose level III = 120/90 (n = 5) and dose level IV = 120/120 (n = 6). All patients showed engraftment: PMN ≥ 0.5 x 109/l at a median interval of 16, 21, 17, 15 days after BMT, and Plt ≥ 30 x 109/l on days 19, 16, 17, 17 respectively. CMVAg-emia was seen in 10 patients at a median interval of 53 days post-BMT (range 33-89) with a median of 10 CMV antigen+ cells (range 1-16). There was a dose effect of foscarnet on CMVAg-emia: respectively 4/5 patients (80%), 2/4 (50%), 3/5 (60%) and 1/6 (18%) at dose levels I, II, III, IV (P = 0.1). CMV disease was seen in 3/9 (33%) at dose levels I, II and 0/11 at dose levels III, IV (P = 0.07). The median number of CMV antigen-positive cells at diagnosis of CMV infection was different: 13 in dose levels I-II and two in dose levels III-IV (P = 0.01). Increased creatininine was seen in 15 patients with a mean of 1.8 mg% (range 1.5-5.7) and was the cause of discontinuation in nine patients (45%). Renal toxicity was reversible in all nine patients. Overall actuarial TRM at 2 years was 31%: 47% for patients at dose levels I-II and 19% for patients at dose levels III-IV. In conclusion, foscarnet exhibits a dose-dependent prophylactic effect on CMVAg-emia, CMV disease and transplant-related mortality with acceptable and reversible renal toxicity.

KW - Bone marrow transplantation

KW - Cytomegalovirus

KW - Foscarnet

UR - http://www.scopus.com/inward/record.url?scp=20244373137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20244373137&partnerID=8YFLogxK

M3 - Article

C2 - 10918402

AN - SCOPUS:20244373137

VL - 26

SP - 23

EP - 29

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 1

ER -